Geode Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-68,699
| Closed | -$8.13M | – | 4785 |
|
|
2021
Q1 | $8.13M | Buy |
68,699
+5,934
| +9% | +$702K | ﹤0.01% | 2502 |
|
|
2020
Q4 | $7.41M | Buy |
62,765
+32,158
| +105% | +$3.73M | ﹤0.01% | 2362 |
|
|
2020
Q3 | $3.4M | Sell |
30,607
-309
| -1% | -$33.2K | ﹤0.01% | 2604 |
|
|
2020
Q2 | $3.16M | Buy |
30,916
+2,914
| +10% | +$312K | ﹤0.01% | 2586 |
|
|
2020
Q1 | $3.02M | Sell |
28,002
-4
| -0% | -$460 | ﹤0.01% | 2438 |
|
|
2019
Q4 | $3.26M | Buy |
28,006
+72
| +0.3% | +$8.34K | ﹤0.01% | 2717 |
|
|
2019
Q3 | $3.2M | Sell |
27,934
-53
| -0.2% | -$5.27K | ﹤0.01% | 2652 |
|
|
2019
Q2 | $2.67M | Buy |
27,987
+2,164
| +8% | +$204K | ﹤0.01% | 2763 |
|
|
2019
Q1 | $2.36M | Buy |
25,823
+1,407
| +6% | +$115K | ﹤0.01% | 2762 |
|
|
2018
Q4 | $1.85M | Buy |
24,416
+1,088
| +5% | +$80.1K | ﹤0.01% | 2816 |
|
|
2018
Q3 | $1.87M | Buy |
23,328
+176
| +0.8% | +$16.4K | ﹤0.01% | 2925 |
|
|
2018
Q2 | $2.3M | Buy |
23,152
+5,412
| +31% | +$468K | ﹤0.01% | 2772 |
|
|
2018
Q1 | $1.44M | Buy |
17,740
+280
| +2% | +$22.6K | ﹤0.01% | 2944 |
|
|
2017
Q4 | $1.38M | Buy |
+17,460
| New | +$1.45M | ﹤0.01% | 2964 |
|
|
2017
Q3 | – | Sell |
-17,116
| Closed | -$1.94M | – | 4128 |
|
|
2017
Q2 | $1.94M | Buy |
17,116
+2,807
| +20% | +$314K | ﹤0.01% | 2751 |
|
|
2017
Q1 | $1.43M | Buy |
14,309
+1,906
| +15% | +$204K | ﹤0.01% | 2841 |
|
|
2016
Q4 | $1.33M | Buy |
12,403
+1,585
| +15% | +$185K | ﹤0.01% | 2853 |
|
|
2016
Q3 | $1.35M | Buy |
10,818
+69
| +0.6% | +$8.14K | ﹤0.01% | 2784 |
|
|
2016
Q2 | $1.14M | Buy |
10,749
+237
| +2% | +$27.5K | ﹤0.01% | 2828 |
|
|
2016
Q1 | $1.2K | Buy |
10,512
+950
| +10% | +$111K | ﹤0.01% | 2784 |
|
|
2015
Q4 | $1.36M | Buy |
9,562
+789
| +9% | +$91.1K | ﹤0.01% | 2737 |
|
|
2015
Q3 | $787K | Sell |
8,773
-605
| -6% | -$63.9K | ﹤0.01% | 3008 |
|
|
2015
Q2 | $1.08M | Buy |
9,378
+954
| +11% | +$100K | ﹤0.01% | 2853 |
|
|
2015
Q1 | $804K | Buy |
8,424
+1,394
| +20% | +$104K | ﹤0.01% | 2982 |
|
|
2014
Q4 | $472K | Buy |
7,030
+1,674
| +31% | +$104K | ﹤0.01% | 3215 |
|
|
2014
Q3 | $288K | Buy |
5,356
+723
| +16% | +$35.6K | ﹤0.01% | 3424 |
|
|
2014
Q2 | $206K | Buy |
+4,633
| New | +$189K | ﹤0.01% | 3514 |
|
Geode Capital Management's CBPO Position: Q2 2021 in Review
Geode Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 68,699 shares — an estimated $8.13M sold.
Geode Capital Management first reported a position in CBPO in Q2 2014 and held it in 27 quarters. The position peaked at $8.13M in Q1 2021. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- Geode Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- Geode Capital Management sold 68,699 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $8.13M.
- Geode Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q2 2014 and held it in 27 quarters.
- Geode Capital Management's China Biologic Products Holdings, Inc. position peaked at $8.13M in Q1 2021.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on Geode Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.